Printer Friendly

OXIGENE COMMENTS ON PHASE I TRIAL REPORT

 NEW YORK, Sept. 29 /PRNewswire/ -- In response to recent inquiries, OXiGENE Inc. (NASDAQ: OXGN; unit - OXGNU; warrant - OXGNW) stated today that it expects to publish the results of its Phase I trial involving a sensitizer of radiation sometime in the fourth quarter of 1993.
 -0- 9/29/93
 /CONTACT: Lisa Powell, executive assistant of OXiGENE, 212-421-0001, or Lory Roston of Lory Roston Associates, 212-877-8590/
 (OXGN)


CO: OXiGENE, Inc. ST: New York IN: MTC SU:

SH-CK -- NY045 -- 6819 09/29/93 12:16 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1993
Words:83
Previous Article:PRUDENTIAL HOME $329 MILLION MORTGAGE CERTIFICATES 1993-39 CLASS A RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:AMEX TO TRADE OPTIONS ON LTV CORPORATION ON OCT. 6
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters